CTEP is in a unique position to facilitate nonclinical and clinical studies involving combinations of investigational anticancer treatments, especially when the agents are developed by more than one pharmaceutical company. At present, CTEP has 102 active INDs, with approximately two-thirds of these being co-developed with members of industry.
CTEP Collaborators and Agents
Jeffrey S. Abrams, M.D., has led the Cancer Therapy Evaluation Program (CTEP) since June 2007. Dr. Abrams came to CTEP in 1993 when he joined as a clinical research scientist to oversee the breast cancer treatment trials portfolio and participate in clinical trials at the NIH Clinical Center and the National Naval Medical Center. More…